Currently, there are 46.28M common shares owned by the public and among those 44.27M shares have been available to trade.
The company’s stock has a 5-day price change of -0.43% and 1.98% over the past three months. PCRX shares are trading 36.68% year to date (YTD), with the 12-month market performance down to -16.67% lower. It has a 12-month low price of $11.16 and touched a high of $31.64 over the same period. PCRX has an average intraday trading volume of 968.57K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.13%, 2.71%, and 26.55% respectively.
Institutional ownership of Pacira BioSciences Inc (NASDAQ: PCRX) shares accounts for 111.29% of the company’s 46.28M shares outstanding.
It has a market capitalization of $1.19B and a beta (3y monthly) value of 0.53. The earnings-per-share (ttm) stands at -$2.29. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.96% over the week and 2.80% over the month.
Earnings per share for the fiscal year are expected to decrease by -11.38%, and 20.81% over the next financial year. EPS should grow at an annualized rate of 11.67% over the next five years, compared to -51.99% over the past 5-year period.
Looking at the support for the PCRX, a number of firms have released research notes about the stock. Truist stated their Hold rating for the stock in a research note on January 30, 2025, with the firm’s price target at $8-$25. Truist coverage for the Pacira BioSciences Inc (PCRX) stock in a research note released on August 13, 2024 offered a Sell rating with a price target of $8. Piper Sandler on their part issued Neutral rating on August 12, 2024.
